Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | short review

ASCO 2013: new developments in lung cancer

verfasst von: Andreas Pircher, MD, Assoc. Prof. Michael Fiegl, MD, Florian Kocher, MD, Assoc. Prof. Wolfgang Hilbe, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

At American Society of Clinical Oncology meeting 2013, some new data were presented, which might have a practice-changing potential. Epidermal growth factor receptor mutational testing was successfully performed in plasma samples, giving hope that tumor biopsies might be replaced by a more comfortable blood analysis. Some studies focused on new second-generation anaplastic lymphoma kinase inhibitors, which showed an impressive efficacy even in crizotinib refractory patients in phase I/II studies and support a sequence of tyrosine kinase inhibitors (TKIs) in this sub-entity of non-small-cell lung cancer (NSCLC). Immunological strategies are worth being tested also in lung cancer, as different strategies have proven first signs of efficacy (MUC1 antigen-specific cancer immunotherapy, programmed cell death ligand 1). Finally, a large phase III trial found that a new oral vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor TKI (nintedanib) combined with docetaxel improved outcome in second-line NSCLC patients when compared with docetaxel monotherapy.
Literatur
1.
Zurück zum Zitat Garon E, Patel J, Myrand S, et al. Translational research (TR) results from pointbreak: a randomized, open-label, phase III study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) followed by maintenance pem + bev (Pem Arm) versus paclitaxel (Pac) + cb + bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8086). Garon E, Patel J, Myrand S, et al. Translational research (TR) results from pointbreak: a randomized, open-label, phase III study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) followed by maintenance pem + bev (Pem Arm) versus paclitaxel (Pac) + cb + bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8086).
2.
Zurück zum Zitat Mok T, Wu YL, Lee JS, et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: a randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). J Clin Oncol. 2013;31 (Suppl; abstr 8021). Mok T, Wu YL, Lee JS, et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: a randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). J Clin Oncol. 2013;31 (Suppl; abstr 8021).
3.
Zurück zum Zitat Timmerman R, Paulus R, Pass H, et al. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J Clin Oncol. 2013;31 (Suppl; abstr 7523). Timmerman R, Paulus R, Pass H, et al. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J Clin Oncol. 2013;31 (Suppl; abstr 7523).
4.
Zurück zum Zitat Pless M, Stupp R, Ris H, et al. Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): a randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). J Clin Oncol. 2013;31 (Suppl; abstr 7503). Pless M, Stupp R, Ris H, et al. Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): a randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). J Clin Oncol. 2013;31 (Suppl; abstr 7503).
5.
Zurück zum Zitat Butts C, Socinski M, Mitchell P, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol. 2013;31 (Suppl; abstr 7500). Butts C, Socinski M, Mitchell P, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol. 2013;31 (Suppl; abstr 7500).
6.
Zurück zum Zitat Lazzari C, Novello S, Barni S, et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol. 2013;31 (Suppl; abstr LBA8005). Lazzari C, Novello S, Barni S, et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol. 2013;31 (Suppl; abstr LBA8005).
7.
Zurück zum Zitat Zinner R, Ross H, Weaver R, et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr LBA8003). Zinner R, Ross H, Weaver R, et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr LBA8003).
8.
Zurück zum Zitat Schuette W, Nagel S, Schneider CP, et al. 65 plus: a randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8013). Schuette W, Nagel S, Schneider CP, et al. 65 plus: a randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8013).
9.
Zurück zum Zitat Planchard D, Mazieres J, Riely G, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31 (Suppl; abstr 8009). Planchard D, Mazieres J, Riely G, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31 (Suppl; abstr 8009).
10.
Zurück zum Zitat Shaw AT, Mehra R, Kim DW, et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol.2013;31 (Suppl; abstr 8010). Shaw AT, Mehra R, Kim DW, et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol.2013;31 (Suppl; abstr 8010).
11.
Zurück zum Zitat Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472–82. doi:10.1158/1078-0432.CCR-11-2906.PubMedCentralPubMedCrossRef Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472–82. doi:10.1158/1078-0432.CCR-11-2906.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Nakagawa K, Kiura K, Nishio M, et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001JP. J Clin Oncol. 2013;31 (Suppl; abstr 8033). Nakagawa K, Kiura K, Nishio M, et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001JP. J Clin Oncol. 2013;31 (Suppl; abstr 8033).
13.
Zurück zum Zitat Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013 Apr 15;73(8):2381–8. doi:10.1158/0008-5472.CAN-12-3932.PubMedCrossRef Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013 Apr 15;73(8):2381–8. doi:10.1158/0008-5472.CAN-12-3932.PubMedCrossRef
14.
Zurück zum Zitat Spigel D, Gettinger S, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8008). Spigel D, Gettinger S, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl; abstr 8008).
15.
Zurück zum Zitat Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol. 2013;31 (Suppl; abstr 8016). Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol. 2013;31 (Suppl; abstr 8016).
16.
Zurück zum Zitat Reck M, Kaiser R, Mellemgaard A, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME lung 1, a randomized, double-blind phase III trial. J Clin Oncol. 2013;31 (Suppl; abstr LBA8011). Reck M, Kaiser R, Mellemgaard A, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME lung 1, a randomized, double-blind phase III trial. J Clin Oncol. 2013;31 (Suppl; abstr LBA8011).
Metadaten
Titel
ASCO 2013: new developments in lung cancer
verfasst von
Andreas Pircher, MD
Assoc. Prof. Michael Fiegl, MD
Florian Kocher, MD
Assoc. Prof. Wolfgang Hilbe, MD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0120-x

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe